Mission and Values

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions.

Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology.

At Urovant Sciences, we aim to advance urological patient care through execution of our core values:

Integrity and Compassion

Our commitment to improving patients’ lives begins with personal integrity and how we treat each other.

Bold Innovation

We deliver bold innovation through diversity of thought, openness to new ideas and adaptation to change.

Achievement Through Collaboration

We achieve excellence by uniquely optimizing our collective individual strengths and expertise.

Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Every team member has the ability to make an impact to our success.
We are ambitious in our approach to improve outcomes for the patients and healthcare providers we serve. To challenge team members and grow careers, we reward innovation, teamwork, and a winning mindset that produces results.
Careers CTA Image

Our History

Founded in 2017, Urovant Sciences is a biopharmaceutical company committed to advancing innovative therapies for urological care.

2017
Vibegron, a β3-adrenergic agonist in development to treat symptoms of overactive bladder (OAB), is acquired as the first compound in the portfolio.
Urovant Sciences establishes corporate offices in Irvine, California.
2018
Urovant Sciences raises $140M in its initial public offering on the NASDAQ Global Select Market under the symbol UROV.
Acquisition of URO-902, the second compound in the portfolio, kickstarts the development of a gene therapy for the treatment of symptoms of OAB.
Phase 3 study of vibegron for patients with OAB begins.
2019
Urovant Sciences launches the Phase 3 study of vibegron for men with benign prostatic hyperplasia (BPH) and OAB.
Phase 2 study of URO-902 for patients with OAB begins.
Primary shareholder, Roivant Sciences, sells its majority ownership of Urovant Sciences to Sumitovant Biopharma Ltd., which is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Urovant Sciences files New Drug Application (NDA) with U.S. Food and Drug Administration for vibegron in OAB.
2020
Executed two collaboration agreements, including the primary care co-promotion agreement with Sunovion.
Reached agreement with Sumitomo Dainippon Pharma to invest in Urovant’s business and for the merger with Sumitovant.
Achieved on-time approval by the U.S. Food & Drug Administration of Urovant’s first commercial product, GEMTESA® (vibegron) 75 mg tablets for patients with overactive bladder on December 23.
2021
Advanced development pipeline, including advancing URO-902, the novel gene therapy being investigated as a treatment for overactive bladder.
Urovant Sciences team grows to 300 employees after onboarding 155 national field sales representatives.
Sumitovant and Urovant Sciences completed merger on March 29.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
Jim Robinson Image
Jim Robinson
President & Chief Executive Officer
Cornelia Haag-Molkenteller Image
Cornelia Haag-Molkenteller, MD, PhD
EVP & Chief Medical Officer
Walt Johnston Image
Walt Johnston
EVP, Commercial
Ajay Bansal Image
Ajay Bansal
EVP, Business Development & Chief Financial Officer
Ryan Card
Ryan Card
EVP & General Counsel
Lisa Klarin
Lisa Klarin
Executive Director and Interim Head, Human Resources
Kenton Stewart Image
Kenton Stewart
EVP, Market Access
Myrtle Potter Image
Myrtle Potter
Shigeyuki Nishinaka Image
Shigeyuki Nishinaka, PhD
Sef Kurstjens Image
Sef Kurstjens, MD, PhD
Pierre Legault
Pierre Legault
Jim Robinson Image
Jim Robinson
Jim Hindman
Jim Hindman
Patent Notice
Please see the following list for U.S. Patents covering Urovant Sciences' Products.